These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29957868)

  • 1. Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.
    Deane AM; Lamontagne F; Dukes GE; Neil D; Vasist L; Barton ME; Hacquoil K; Ou X; Richards D; Stelfox HT; Mehta S; Day AG; Chapman MJ; Heyland DK
    JPEN J Parenter Enteral Nutr; 2018 Jul; 42(5):949-959. PubMed ID: 29957868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.
    Chapman MJ; Deane AM; O'Connor SL; Nguyen NQ; Fraser RJ; Richards DB; Hacquoil KE; Vasist Johnson LS; Barton ME; Dukes GE
    Crit Care; 2016 Aug; 20(1):232. PubMed ID: 27476581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manometric evaluation of the motilin receptor agonist camicinal (GSK962040) in humans.
    Deloose E; Depoortere I; de Hoon J; Van Hecken A; Dewit OE; Vasist Johnson LS; Barton ME; Dukes GE; Tack J
    Neurogastroenterol Motil; 2018 Jan; 30(1):. PubMed ID: 28782145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.
    Hellström PM; Tack J; Johnson LV; Hacquoil K; Barton ME; Richards DB; Alpers DH; Sanger GJ; Dukes GE
    Br J Pharmacol; 2016 Jun; 173(11):1768-77. PubMed ID: 26924243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of hyperosmolar medications administered via nasogastric or nasoduodenal tubes and feeding adequacy, food intolerance and gastrointestinal complications amongst critically ill patients: A retrospective study.
    Wesselink E; Koekkoek KWAC; Looijen M; van Blokland DA; Witkamp RF; van Zanten ARH
    Clin Nutr ESPEN; 2018 Jun; 25():78-86. PubMed ID: 29779822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fat-Modified Enteral Formula Improves Feeding Tolerance in Critically Ill Patients: A Multicenter, Single-Blind, Randomized Controlled Trial.
    Qiu C; Chen C; Zhang W; Kou Q; Wu S; Zhou L; Liu J; Ma G; Chen J; Chen M; Luo H; Zhang X; Lai J; Yu Z; Yu X; Liao W; Guan X; Ouyang B
    JPEN J Parenter Enteral Nutr; 2017 Jul; 41(5):785-795. PubMed ID: 26350918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.
    Hobson R; Farmer AD; Dewit OE; O'Donnell M; Hacquoil K; Robertson D; Barton ME; Dukes GE
    Neurogastroenterol Motil; 2015 Nov; 27(11):1629-37. PubMed ID: 26348542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Marrinan SL; Otiker T; Vasist LS; Gibson RA; Sarai BK; Barton ME; Richards DB; Hellström PM; Nyholm D; Dukes GE; Burn DJ
    Mov Disord; 2018 Feb; 33(2):329-332. PubMed ID: 29278279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, risk factors, clinical consequences, and treatment of enteral feed intolerance during critical illness.
    Gungabissoon U; Hacquoil K; Bains C; Irizarry M; Dukes G; Williamson R; Deane AM; Heyland DK
    JPEN J Parenter Enteral Nutr; 2015 May; 39(4):441-8. PubMed ID: 24637246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study.
    MacLaren R; Kuhl DA; Gervasio JM; Brown RO; Dickerson RN; Livingston TN; Swift K; Headley S; Kudsk KA; Lima JJ
    Crit Care Med; 2000 Feb; 28(2):438-44. PubMed ID: 10708180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, Risk Factors, and Clinical Consequence of Enteral Feeding Intolerance in the Mechanically Ventilated Critically Ill: An Analysis of a Multicenter, Multiyear Database.
    Heyland DK; Ortiz A; Stoppe C; Patel JJ; Yeh DD; Dukes G; Chen YJ; Almansa C; Day AG
    Crit Care Med; 2021 Jan; 49(1):49-59. PubMed ID: 33148950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastric emptying: Trial of nasointestinal feeding versus nasogastric feeding plus prokinetics.
    Taylor SJ; Allan K; McWilliam H; Manara A; Brown J; Greenwood R; Toher D
    Clin Nutr ESPEN; 2016 Aug; 14():1-8. PubMed ID: 28531392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma erythromycin concentrations predict feeding outcomes in critically ill patients with feed intolerance.
    Nguyen NQ; Grgurinovich N; Bryant LK; Burgstad CM; Chapman MJ; Holloway RH; Mangoni AA; Fraser RJ
    Crit Care Med; 2011 Apr; 39(4):868-71. PubMed ID: 21297459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind, placebo-controlled trial of the prokinetic agent erythromycin in the postoperative recovery of infants with gastroschisis.
    Curry JI; Lander AD; Stringer MD;
    J Pediatr Surg; 2004 Apr; 39(4):565-9. PubMed ID: 15065029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteral nutrition delivery and energy expenditure in medical intensive care patients.
    Petros S; Engelmann L
    Clin Nutr; 2006 Feb; 25(1):51-9. PubMed ID: 16216393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intolerance to intragastric enteral nutrition in critically ill patients: complications and management.
    MacLaren R
    Pharmacotherapy; 2000 Dec; 20(12):1486-98. PubMed ID: 11130221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial.
    Heyland DK; van Zanten ARH; Grau-Carmona T; Evans D; Beishuizen A; Schouten J; Hoiting O; Bordejé ML; Krell K; Klein DJ; Gonzalez J; Perez A; Brown R; James J; Harris MS;
    Intensive Care Med; 2019 May; 45(5):647-656. PubMed ID: 31062046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gastrointestinal tolerance to two enteral feeding protocols in critically ill patients: a prospective, randomized controlled trial.
    Pinilla JC; Samphire J; Arnold C; Liu L; Thiessen B
    JPEN J Parenter Enteral Nutr; 2001; 25(2):81-6. PubMed ID: 11284474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.
    Lewis K; Alqahtani Z; Mcintyre L; Almenawer S; Alshamsi F; Rhodes A; Evans L; Angus DC; Alhazzani W
    Crit Care; 2016 Aug; 20(1):259. PubMed ID: 27527069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility.
    Sanger GJ; Westaway SM; Barnes AA; Macpherson DT; Muir AI; Jarvie EM; Bolton VN; Cellek S; Näslund E; Hellström PM; Borman RA; Unsworth WP; Matthews KL; Lee K
    Neurogastroenterol Motil; 2009 Jun; 21(6):657-64, e30-1. PubMed ID: 19374732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.